110 related articles for article (PubMed ID: 32228818)
1. Impact of smoking on metabolic changes and effectiveness of drugs used for lung cancer.
Perlík F
Cent Eur J Public Health; 2020 Mar; 28(1):53-58. PubMed ID: 32228818
[TBL] [Abstract][Full Text] [Related]
2. Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer.
O'Malley M; King AN; Conte M; Ellingrod VL; Ramnath N
J Thorac Oncol; 2014 Jul; 9(7):917-926. PubMed ID: 24926542
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.
Endo-Tsukude C; Sasaki JI; Saeki S; Iwamoto N; Inaba M; Ushijima S; Kishi H; Fujii S; Semba H; Kashiwabara K; Tsubata Y; Hayashi M; Kai Y; Saito H; Isobe T; Kohrogi H; Hamada A
Biol Pharm Bull; 2018; 41(1):47-56. PubMed ID: 29311482
[TBL] [Abstract][Full Text] [Related]
4. Impact of smoking on lung cancer treatment effectiveness: a review.
Condoluci A; Mazzara C; Zoccoli A; Pezzuto A; Tonini G
Future Oncol; 2016 Sep; 12(18):2149-61. PubMed ID: 27424719
[TBL] [Abstract][Full Text] [Related]
5. Drug interactions with tobacco smoking. An update.
Zevin S; Benowitz NL
Clin Pharmacokinet; 1999 Jun; 36(6):425-38. PubMed ID: 10427467
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of smoking cessation in subjects with cancer: a 30-year review.
Florou AN; Gkiozos IC; Tsagouli SK; Souliotis KN; Syrigos KN
Respir Care; 2014 Dec; 59(12):1924-36. PubMed ID: 25185148
[TBL] [Abstract][Full Text] [Related]
7. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
[TBL] [Abstract][Full Text] [Related]
8. "Impact of Smoking Cessation Treatment" on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study.
Pezzuto A; Stumbo L; Russano M; Crucitti P; Scarlata S; Caricato M; Tonini G
Recent Pat Anticancer Drug Discov; 2015; 10(3):342-51. PubMed ID: 26246248
[TBL] [Abstract][Full Text] [Related]
9. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.
Desai HD; Seabolt J; Jann MW
CNS Drugs; 2001; 15(6):469-94. PubMed ID: 11524025
[TBL] [Abstract][Full Text] [Related]
10. Increased cytochrome P450 and aryl hydrocarbon receptor in bronchial epithelium of heavy smokers with non-small cell lung carcinoma carries a poor prognosis.
Oyama T; Sugio K; Uramoto H; Iwata T; Onitsuka T; Isse T; Nozoe T; Kagawa N; Yasumoto K; Kawamoto T
Front Biosci; 2007 May; 12():4497-503. PubMed ID: 17485391
[TBL] [Abstract][Full Text] [Related]
11. Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation.
Erdogan B; Kodaz H; Karabulut S; Cinkaya A; Tozkir H; Tanriverdi O; Cabuk D; Hacioglu MB; Turkmen E; Hacibekiroglu I; Uzunoglu S; Cicin I
Bosn J Basic Med Sci; 2016 Nov; 16(4):280-285. PubMed ID: 27371767
[TBL] [Abstract][Full Text] [Related]
12. Carcinogen metabolism and DNA adducts in human lung tissues as affected by tobacco smoking or metabolic phenotype: a case-control study on lung cancer patients.
Bartsch H; Petruzzelli S; De Flora S; Hietanen E; Camus AM; Castegnaro M; Geneste O; Camoirano A; Saracci R; Giuntini C
Mutat Res; 1991; 250(1-2):103-14. PubMed ID: 1944327
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
14. Smoking intensity, oxidative stress and chemotherapy in nonsmall cell lung cancer: a correlated prognostic study.
Gupta A; Srivastava S; Prasad R; Natu SM; Mittal B; Negi MP; Srivastava AN
Biosci Trends; 2009 Oct; 3(5):191-9. PubMed ID: 20103846
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS).
Smit EF; Wu YL; Gervais R; Zhou C; Felip E; Feng J; Guclu SZ; Hoiczyk M; Dorokhova E; Freudensprung U; Grange S; Perez-Moreno PD; Mitchell L; Reck M
Lung Cancer; 2016 Sep; 99():94-101. PubMed ID: 27565921
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.
Zugazagoitia J; Puente J; González-Larriba JL; Manzano A; Sotelo M; Hernández S; Sanz J; Pérez P; Díaz-Rubio E
Oncology; 2013; 84(5):255-64. PubMed ID: 23428780
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
[TBL] [Abstract][Full Text] [Related]
18. Analysis of DNA adducts in smokers' lung and urothelium by 32P-postlabelling: metabolic phenotype dependence and comparisons with other exposure markers.
Bartsch H; Castegnaro M; Camus AM; Schouft A; Geneste O; Rojas M; Alexandrov K
IARC Sci Publ; 1993; (124):331-40. PubMed ID: 8225503
[TBL] [Abstract][Full Text] [Related]
19. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
20. Long-lasting effects of tobacco smoking on pulmonary drug-metabolizing enzymes: a case-control study on lung cancer patients.
Petruzzelli S; Camus AM; Carrozzi L; Ghelarducci L; Rindi M; Menconi G; Angeletti CA; Ahotupa M; Hietanen E; Aitio A
Cancer Res; 1988 Aug; 48(16):4695-700. PubMed ID: 3135117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
